Abstract | RATIONALE: METHOD: Forty-three inpatients with DSM-IV schizophrenic disorder participated in a randomized double-blind study. Reboxetine (4 mg/day) with betahistine (48 mg/day) (N = 29) or placebo (N = 14) was co-administered with olanzapine (10 mg/day) for 6 weeks. Mental status was assessed at baseline and endpoint with relevant rating scales. Intention-to-treat method was used for statistical analysis. RESULTS: Seven patients in the study group and four in the placebo group discontinued the trial. At the end of the trial, patients in the olanzapine/ reboxetine + betahistine group gained significantly less weight than those in the olanzapine/placebo group [2.02 ± 2.37 and 4.77 ± 3.16 kg, respectively; t = 2. 89, degrees of freedom (df) = 41, p = 0.006]. The weight-attenuating effect of this combination was twofold larger than the weight-attenuating effect previously demonstrated with reboxetine alone. Significantly fewer patients in the study group than in the comparison group increased their initial weight by >7 %, the cutoff for clinically significant weight gain [3/29 (10.3 %) and 6/14 (42.9 %), respectively; χ (2) = 6.03, df = 1, p = 0.014]. The reboxetine- betahistine combination was safe and well tolerated. CONCLUSIONS:
|
Authors | Michael Poyurovsky, Camil Fuchs, Artashez Pashinian, Adva Levi, Ronit Weizman, Abraham Weizman |
Journal | Psychopharmacology
(Psychopharmacology (Berl))
Vol. 226
Issue 3
Pg. 615-22
(Apr 2013)
ISSN: 1432-2072 [Electronic] Germany |
PMID | 23239133
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic Uptake Inhibitors
- Antipsychotic Agents
- Histamine Agonists
- Morpholines
- Benzodiazepines
- Reboxetine
- Olanzapine
- Betahistine
|
Topics |
- Adrenergic Uptake Inhibitors
(administration & dosage, adverse effects, therapeutic use)
- Adult
- Antipsychotic Agents
(administration & dosage, adverse effects, therapeutic use)
- Benzodiazepines
(administration & dosage, adverse effects, therapeutic use)
- Betahistine
(administration & dosage, adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Histamine Agonists
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Morpholines
(administration & dosage, adverse effects, therapeutic use)
- Olanzapine
- Reboxetine
- Schizophrenia
(drug therapy)
- Treatment Outcome
- Weight Gain
(drug effects)
- Young Adult
|